Abraham Morgentaler, MD, FACS, describes the phenomenon of testosterone flare following prostate cancer treatment with luteinizing hormone-releasing hormone (LHRH) agonists and argues that this flare does not necessarily cause disease progression. He also discusses the effects of testosterone therapy in patients with untreated prostate cancer.
Read More
Abraham Morgentaler, MD, explains new concepts that could subvert the long-held belief that high levels of testosterone exacerbate prostate cancer growth. He discusses the androgen saturation model, as well as the benefits of testosterone therapy for patients’ quality of life.
Read More
Dr. Abraham Morgentaler presented “Testosterone and Prostate Cancer: Is There a Link?”...
Read More
Dr. Abraham Morgentaler spoke at the 25th International Prostate Cancer Update on Saturday,...
Read More